STAAR Surgical Appoints Scott Barnes, MD, as New CMO

October 6, 2017: By Jon Swedien

STAAR Surgical logoSTAAR Surgical has appointed Scott D. Barnes, MD, to be its chief medical officer, a newly created position, the Monrovia, California, company announced Oct. 2.

Barnes will report to Caren Mason, STAAR’s president and CEO.

He will also serve on the executive management team and provide strategic guidance for STAAR’s medical affairs, professional affairs, and product development pathways. As well, Barnes will lead the company’s surgeon training, certification programs, and surgeon working groups, STAAR said.

Since 2012, Barnes has served as chief of ophthalmology services at Womack Army Medical Center in Fort Bragg, North Carolina.

Barnes has personally implanted more than 3,000 implantantable contact lenses in the eyes of soldiers, STAAR said.

He joined Womack in 2004 as chief of ophthalmology and refractive surgery and served as a theater ophthalmology consultant in Iraq and Afghanistan during 2005. In 2006, he returned to Womack as chief of refractive surgery, and, in 2008, he was designated Army Surgeon General A, which is similar to the professor level in a civilian institution.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022